The Life Sciences team advised Blackstone Life Sciences on its strategic, risk-sharing financing collaboration with Sanofi, in which Blackstone will provide Sanofi with up to €300 million in funding to support the clinical development program for a subcutaneous formulation of Sarclisa, an anti-CD38 antibody approved in a number of countries for the treatment of multiple myeloma. In exchange, Blackstone will be eligible to receive royalties on future sales of the subcutaneous formulation.
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives.
The Goodwin team was led by Richard Hoffman and Yasin Akbari and included Dan Karelitz, Nicole Spiteri, EA Weeks, and Carolyn Nguyen.
For additional details, please read Sanofi’s press release and coverage in Fierce Pharma and Seeking Alpha.